Product Description
Interferon beta-1a controls the symptoms of MS but does not cure it. Interferon beta-1a is in a class of medications called immunomodulators. It works by decreasing inflammation and preventing nerve damage that may cause symptoms of multiple sclerosis. (Sourced from: https://medlineplus.gov/druginfo/meds/a693040.html)
Mechanisms of Action: IFR Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous,Intramuscular
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela
Approved Indications: Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis
Known Adverse Events: Abdominal Pain | Headache | Pain Unspecified | Insomnia | Lymphopenia | Neutropenia | Myalgia | Asthenia | Leukopenia | Chills
Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Canada, Colombia, Croatia, Germany, Hungary, India, Iran, Ireland, Japan, Nepal, Netherlands, New Zealand, Pakistan, Portugal, Romania, Saudi Arabia, Spain, United Kingdom, United States
Active Clinical Trial Count: 8
Highest Development Phases
Phase 3: COVID-19|Influenza, Human|Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting|Pneumonia
Phase 2: Total Knee Arthroplasty
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| REMAP-CAP | P3 |
Recruiting |
Influenza, Human|COVID-19|Pneumonia |
2026-02-01 |
|
| 2018-001292-21 | P3 |
Active, not recruiting |
Multiple Sclerosis |
2025-07-04 |
|
| DisCoVeRy | P3 |
Active, not recruiting |
COVID-19 |
2023-03-06 |
|
| PEG.CIN.AZ.94.III | P3 |
Completed |
Multiple Sclerosis, Relapsing-Remitting |
2022-04-27 |
95% |